Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.65 |
| ▸ | CTSD | P07339 | 9/20 | 0.56 |
| ▸ | CTSE | P14091 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353536 | 0.85 | BACE1 (0.59) | BACE1CTSDCTSE | |
| SCHEMBL2530306 | 0.82 | BACE1 (0.70) | BACE1CTSDCTSE | |
| SCHEMBL2528616 | 0.82 | BACE1 (0.77) | BACE1CTSDCTSE | |
| SCHEMBL2528299 | 0.81 | BACE1 (0.96) | BACE1CTSDCTSE | |
| SCHEMBL2532078 | 0.80 | BACE1 (0.73) | BACE1CTSDCTSE | |
| SCHEMBL2526933 | 0.80 | BACE1 (0.66) | BACE1CTSDCTSE | |
| SCHEMBL2356431 | 0.79 | BACE1 (0.53) | BACE1CTSDCTSE | |
| SCHEMBL2534452 | 0.77 | BACE1 (0.88) | BACE1CTSDCTSE | |
| SCHEMBL2349979 | 0.76 | BACE1 (0.73) | BACE1CTSDCTSE | |
| SCHEMBL2350865 | 0.76 | BACE1 (0.56) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008250-B2 | 1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-9,10-dimethyl-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(19),15,17-triene-8,11-dione; secretase inhibitor; neurological, vascular disorders, beta-amyloid generation/aggregation; Alzheimer's disease, Down's Syndrome, cognitive impairment, amyloid neuropathies | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | BACE1 1/4885CTSD 15/4885CTSE 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.